From Yahoo Finance: 2025-06-23 01:38:00

Barclays analyst Gena Wang maintains a Buy rating on BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) with a price target of $86.00. The company reported $745.15 million in revenue and $185.69 million in net profit for the quarter ending March 31, with sales of $648.83 million and net profit of $88.66 million the previous year. Despite past struggles, analysts see long-term potential in BioMarin’s genetic-disease therapies portfolio. The company’s internal pipeline and ability to grow through strategic acquisitions position it well for future success. No disclosures were reported.



Read more at Yahoo Finance: Barclays Initiates BioMarin Pharmaceutical Inc. (BMRN) with a Buy Rating